Sumitomo Chemical Co., Ltd. · TSE:4005
Sumitomo Chemical — Q3 2026 Earnings Presentation
28 slides from Sumitomo Chemical's earnings presentation, Feb 3, 2026
Slide 1: Financial Results for FY2025 Third Quarter
Financial Results for FY2025 Third Quarter (April 1, 2025 – December 31, 2025) February 3, 2026
Slide 2: Cautionary Statement
(Cautionary Statement) Statements made in this material with respect to Sumitomo Chemical’s current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management’s assu
Slide 3: Contents
Contents 2 1. Consolidated Financial Results for （Reference） FY2025 Third Quarter Sales Revenue Summary for Q3 FY2025 ･･････････････････････ 4 by Reporting Segment (Quarterly)･････････････････ 21 Consolidated Financial Results Summary････････ 5 Core Operating Income Sales Revenue by Reporting Segmen
Slide 4: 1. Consolidated Financial Results for FY2025 Third Quarter
1. Consolidated Financial Results for FY2025 Third Quarter
Slide 5: Summary for Q3 FY2025
Summary for Q3 FY2025 4 Core Operating Income Net Income Attributable to Owners (Billions of yen) of the Parent (Billions of yen) FY2025 FY2025 Q3 FY2024 Q3 FY2025 Forecast Q3 FY2024 Q3 FY2025 Forecast (ann. in Nov.) (ann. in Nov.) 60.1 186.8 185.0 28.6 87.4 45.0 Substantial gain on sale of business
Slide 6: Consolidated Financial Results Summary
Consolidated Financial Results Summary 5 (Billions of yen) Variance Q3 FY2025 Q3 FY2024 Variance Ratio Sales revenue 1,706.3 1,904.8 (198.5) (10.4)% Core operating income 186.8 60.1 126.8 211.1% of which equity-method investments (43.2) (53.3) 10.1 - Total non-recurring items (breakdown below) (6.4)
Slide 7: Sales Revenue by Reporting Segment
Sales Revenue by Reporting Segment 6 (Billions of yen) Foreign Sales Shipping currency Q3 FY2025 Q3 FY2024 Variance Ratio price volume conversion variance variance variance Agro & Life Solutions 346.9 363.1 (16.2) (4.5)% (1.5) (8.4) (6.3) ICT & Mobility Solutions 431.8 461.2 (29.4) (6.4)% (10.0) (8.
Slide 8: Core Operating Income by Reporting Segment
Core Operating Income by Reporting Segment 7 (Billions of yen) Shipping Price Cost volume Q3 FY2025 Q3 FY2024 Variance variance variance variance and other Agro & Life Solutions 28.1 19.5 8.6 2.5 (2.0) 8.1 ICT & Mobility Solutions 46.5 59.7 (13.2) (8.5) (1.0) (3.7) Advanced Medical Solutions 0.3 1.2
Slide 9: Core Operating Income Analysis: Agro & Life Solutions
Core Operating Income Analysis by Reporting Segment 8 Agro & Life Solutions Total ¥ 28.1 billion ¥ 8.6 billion from Q3 FY2024 8.1 2.5 (2.0) 28.1 19.5 Q3 FY2024 Price Cost Volume Q3 FY2025 and other Price Crop Protection Improved trade terms for overseas crop protection products variance Volume Stron
Slide 10: Core Operating Income Analysis: ICT & Mobility Solutions
Core Operating Income Analysis by Reporting Segment 9 ICT & Mobility Solutions Total ¥ 46.5 billion ¥ (13.2) billion from Q3 FY2024 (8.5) (1.0) (3.7) 59.7 46.5 Q3 FY2024 Price Cost Volume Q3 FY2025 and other Price Displays Decline in the selling price of display-related materials variance Displays D
Slide 11: Core Operating Income Analysis: Advanced Medical Solutions
Core Operating Income Analysis by Reporting Segment 10 Advanced Medical Solutions Total ¥ 0.3 billion ¥ (0.9) billion from Q3 FY2024 0.0 1.2 (0.5) (0.4) 0.3 Q3 FY2024 Price Cost Volume Q3 FY2025 and other Volume and other Decrease in sales at affiliated companies variances
Slide 12: Core Operating Income Analysis: Essential & Green Materials
Core Operating Income Analysis by Reporting Segment 11 Essential & Green Materials Total ¥ 19.8 billion ¥ 64.1 billion from Q3 FY2024 52.6 19.8 (44.3) 12.5 (1.0) Q3 FY2024 Price Cost Volume Q3 FY2025 and other Price Profit margins improved in synthetic resins and alumina variance Volume Gain on part
Slide 13: Core Operating Income Analysis: Sumitomo Pharma
Core Operating Income Analysis by Reporting Segment 12 Sumitomo Pharma Total ¥ 111.2 billion ¥ 86.9 billion from Q3 FY2024 79.4 8.0 111.2 24.4 (0.5) Q3 FY2024 Price Cost Volume Q3 FY2025 and other Price NHI drug price revisions in Japan variance Cost Lower fixed costs variance Volume Gain posted on
Slide 14: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position 13 (Billions of yen) 31-Dec-25 31-Mar-25 Variance 31-Dec-25 31-Mar-25 Variance Current assets 1,600.8 1,583.1 17.7 Liabilities 2,244.3 2,365.4 (121.1) Cash and 214.8 209.8 4.9 Trade and other payables 473.6 488.1 (14.5) cash equivalents Trade and other re
Slide 15: Consolidated Statement of Cash Flows
Consolidated Statement of Cash Flows 14 (Billions of yen) Q3 FY2025 Q3 FY2024 Variance FY2024 Cash flows from operating activities 111.6 140.7 (29.1) 233.0 Cash flows from investing activities (39.8) 56.7 (96.6) 85.2 Free cash flows 71.8 197.5 (125.7) 318.3 Cash flows from financing activities (100.
Slide 16: 2. Outlook for FY2025
2. Outlook for FY2025 > SUMITOMO CHEMICAL
Slide 17: FY2025 Outlook for the Business Environment
FY2025 Outlook for the Business Environment 16
Slide 18: Summary of Financial Forecast for FY2025
Summary of Financial Forecast for FY2025 17 Forecast for FY2025 Core operating income: projected to be 200.0 billion yen, an upward Core Operating Income Trend revision from 185.0 billion yen （Billions of yen） Net income attributable to owners of the parent: projected to reach 200.0 200.0 55.0 billi
Slide 19: Performance Forecast for FY2025
Performance Forecast for FY2025 18 (Billions of yen) FY2025 FY2025 Variance ｆorecast Variance FY2024 forecast (announced in Nov.) ratio Sales revenue 2,300.0 2,290.0 10.0 0.4% 2,606.3 Core operating income 200.0 185.0 15.0 8.1% 140.5 Net income attributable to owners of the parent 55.0 45.0 10.0 22.
Slide 20: Sales Revenue and Core Operating Income by Reporting Segment
Sales Revenue and Core Operating Income by Reporting Segment 19 (Billions of yen) FY2025 FY2025 Variance FY2024 forecast forecast (announced in Nov.) Agro & Life Solutions Sales Revenue 530.0 530.0 - 540.2 Core Operating Income 55.0 55.0 - 55.0 ICT & Mobility Solutions Sales Revenue 560.0 550.0 10.0
Slide 21: (Reference)
(Reference) > SUMITOMO CHEMICAL
Slide 22: Sales Revenue by Reporting Segment (Quarterly)
Sales Revenue by Reporting Segment (Quarterly) 21 (Billions of yen) FY2024 FY2025 Q4 Total Q1 Q2 Q3 Q4 Q1 Q2 Q3 (Forecast) Forecast Agro & Life Solutions 106.4 118.6 138.1 177.1 96.9 116.1 133.9 183.1 530.0 ICT & Mobility Solutions 152.7 154.8 153.8 145.8 137.4 146.1 148.3 128.2 560.0 Advanced Medic
Slide 23: Core Operating Income by Reporting Segment (Quarterly)
Core Operating Income by Reporting Segment (Quarterly) 22 (Billions of yen) FY2024 FY2025 Q4 Total Q1 Q2 Q3 Q4 Q1 Q2 Q3 (Forecast) Forecast Agro & Life Solutions 4.9 9.2 5.4 35.5 2.2 9.0 16.9 26.9 55.0 ICT & Mobility Solutions 21.2 22.4 16.1 10.8 18.4 14.7 13.4 8.5 55.0 Advanced Medical Solutions 0.
Slide 24: Sales Revenue Analysis by Reporting Segment
Sales Revenue Analysis by Reporting Segment 23 Agro & Life Solutions Total ¥ 346.9 billion ¥ (16.2) billion from Q3 FY2024 (1.5) Price (8.4) (1.5) (6.3) 363.1 Volume 346.9 (8.4) Decrease in shipments of methionine Foreign exchange Q3 FY2024 Price Volume FX Q3 FY2025 (6.3) ICT & Mobility Solutions
Slide 25: Sales Revenue Analysis by Reporting Segment
Sales Revenue Analysis by Reporting Segment 24 Advanced Medical Solutions 0.0 0.1 Total ¥ 35.6 billion ¥ (5.1) billion from Q3 FY2024 (5.2) Price 0.0 40.7 Volume Decrease in orders for affiliated company 35.6 (5.2) business Increase in shipments for oligonucleotide Foreign exchange business Q3 F
Slide 26: Sales Revenue Analysis by Reporting Segment
Sales Revenue Analysis by Reporting Segment 25 Sumitomo Pharma 61.7 Total ¥ 346.4 billion ¥ 53.6 billion from Q3 FY2024 (7.6) Price (0.5) (0.5) NHI drug price revisions in Japan 346.4 Volume 292.8 61.7 Expanded sales of ORGOVYX® and GEMTESA® Foreign exchange Q3 FY2024 Price Volume FX Q3 FY2025 (
Slide 27: Major Group Companies
Major Group Companies 26 Sales Revenue Company Profit Q3 FY2025 Q3 FY2024 The Polyolefin Company (Singapore) 560 645 Improvement in profit margin (Millions of USD) PCS 1,637 1,820 Deterioration in profit margins (Millions of USD) Rabigh Refining and Petrochemical Company 24,356 27,952 Improvement in
Slide 28: Crop Protection Product Sales by Region
Crop Protection Product Sales by Region 27 (Billions of yen) Q3 FY2025 Q3 FY2024 Variance Reasons for Change Japan 53.1 44.9 8.2 • Increase in shipments through moving up the sales period, etc. North America 52.4 55.0 (2.6) • Foreign currency conversion variance (JPY strengthening against the BRL) C
Sumitomo Chemical Company — Q3 2026 Earnings Presentation on 6ix